Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 170

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 19
Chunk 170
---

statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.

F-18

NOTE 4 - ACCOUNTS RECEIVABLE, NET

Accounts receivable, net consists of the following:

                                                December 31,                                   
                                                2024                          2023             
 ───────────────────────────────────────────────────────────────────────────────────────────────
  Accounts receivable                           $                 49,264      $         9,393  
  Less: allowance for expected credit loss                          ( 19                 ( 19  
                                                $                 49,245      $         9,374  

As of the end of each of the financial year, the
aging analysis of accounts receivable, net of allowance for expected credit loss, based on the invoice date is as follows:

  December 31,                        
  2024                          2023  
 ──────────────────────────────────────
  Within 90 days $49,245      $9,374  
  $49,245                     $9,374  

The movement of allowances for expected credit
loss is as follow:

                                          December 31,                                
                                          2024                        2023            
  Balance at beginning of the year        $                 ( 19      $         ( 26  
 ──────────────────────────────────────────────────────────────────────────────────────
  Reversal of expected credit losses                        -                      7  
  Ending balance                          $                 ( 19      $         ( 19  

NOTE 5 - INVENTORIES

Inventories consist of the following:

  December 31,                                                                                    
  2024                                                                                      2023  
 ──────────────────────────────────────────────────────────────────────────────────────────────────
  Medicines, consumables and reagents for clinical and laboratory analyses $80,813      $126,264  
  $80,813                                                                               $126,264  

NOTE 6 - DEPOSITS, PREPAYMENT, OTHER RECEIVABLES AND
DEFERRED IPO COST, NET

Deposits, prepayment, other receivables and deferred
IPO cost, net consist of the following:

                                                     December 31,                                          
                                                     2024                             2023                 
 ─────────